Scott Gottlieb Quotes
The key to the generic-drug economic model is to keep entry prices low enough to attract multiple competitors.
Gottlieb, Scott. "The FDA's Generic-Drug Monopoly." The Wall Street Journal, 19 Aug. 2016.
Patents, copyrights, and franchises are but 3 common (and legal) ways of obtaining a onopoly position.See Adam Smith {627790} for a similar thought.
Most businesses attempt to gain monopolistic positions and avoid price and other competition as much as possible. See {633636} .
The “inflated prices” refers to the fact Americans pay more for pharmaceuticals than any other country in the world as the American government allows the companies to charge any amounts while other governments either negotiate or mandate much lower prices.
Scott Gottlieb is an American physician and investor who served as the 23rd commissioner of the Food and Drug Administration (FDA) from 2017 until April 2019. He is presently a resident fellow at the conservative think tank the American Enterprise Institute (AEI), a partner at the venture capital firm New Enterprise Associates (NEA), a member of the board of directors of drug maker Pfizer, Inc, a member of the board of directors of Illumina, Inc., and a contributor to the cable financial news network CNBC. Before becoming FDA commissioner, he was a clinical assistant professor at New York University School of Medicine, the FDA deputy commissioner for medical and scientific affairs, a venture partner with New Enterprise Associates, a member of the policy board of the Leukemia & Lymphoma Society, a senior official at the Centers for Medicare and Medicaid Services, and a member of the Federal Health Information Technology Policy Committee, which advises the United States Department of Health and Human Services on healthcare information technology. He was previously a resident fellow at AEI from 2007 to 2017 prior to joining the FDA as commissioner in May 2017.